Clinical Pharmacology of Cyclophosphamide

Cancer Research

Volumn 33, Issue 2, 1973, Pages 226-233

  Bagley, Charles M ^a   Bostick, Frieda W ^a   DeVita, Vincent T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CARBON; CYCLOPHOSPHAMIDE; NITROBENZENE DERIVATIVE; PLASMA PROTEIN; PREDNISOLONE; PYRIDINE DERIVATIVE;

ALKYLATION; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; FECES; HALF LIFE TIME; HUMAN; LIVER TUMOR; METABOLISM; NEOPLASM; PROTEIN BINDING; TIME; ULTRAFILTRATION; URINE;

ALKYLATION; ALLOPURINOL; BLOOD PROTEINS; CARBON ISOTOPES; CYCLOPHOSPHAMIDE; FECES; HALF-LIFE; HUMAN; KIDNEY FAILURE, CHRONIC; LIVER NEOPLASMS; NEOPLASMS; NITROBENZENES; PREDNISOLONE; PROTEIN BINDING; PYRIDINES; TIME FACTORS; ULTRAFILTRATION;

EID: 0015577195     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bagley, C. M., Jr., DeVita, V. T., Jr., Berard, C. W., and Canellos, G. P. Advanced Lymphosarcoma: Intensive Cyclical Combination Chemotherapy with Cyclophosphamide, Vincristine, and Prednisone. Ann. Internal Med., 76: 227–234, 1972.
2. Bakke, J. E., Fiel, V. J., Fjelstul, C. E., and Thacker, E. J. Metabolism of Cyclophosphamide by Sheep. J. Agr. Food Chem., 20: 384–388, 1972.
3. Brock, N., Gross, R., Hohorst, J. J., Klein, H. O., and Schneider, B. Activation of Cyclophosphamide in Man and Animals. Cancer, 27: 1512–1529, 1971.
4. Brock, N., and Hohorst, H. J. Ueber Aktivierung von Cyclophosphamid in vivo und in vitro. Artzneimittel-Forsch., 13: 1021–1031, 1963.
5. Brown, H. D., Chattopadhyay, S. K., Pennington, S. N., Spratt, J. S., and Morris, H. P. Mixed Function Oxidation in Tumors. Brit. Med. J., 25: 135–141, 1971.
6. 32Labelled Cyclophosphamide in Albino Rats and in Humans. Indian J. Cancer, 6: 153-164, 1969.
7. Conney, A. H. Pharmacological Implication of Microsomal Enzyme Induction. Pharmacol. Rev., 19: 317–366, 1967.
8. 14C-Cyclophosphamide: Comparative Drug Metabolism Studies on African and American Patients with Lymphosarcoma and Burkitt's Tumor. In: H. Umezawa (ed.), Progress in Antimicrobial and Anticancer Chemotherapy, Vol. 2, pp. 218–225. Tokyo, Japan: University of Tokyo Press, 1970.
9. Dixon, R. L., and Adamson, R. H. Antitumor Activity and Pharmacologic Disposition of Cytosine Arabinoside (NSC-63878). Cancer Chemotherapy Rept., 48: 11–16, 1965.
10. Donelli, M. G., Franchi, G., and Rosso, R. The Effect of Cytotoxic Agents on Drug Metabolism. European J. Cancer, 7: 361–364, 1970.
11. Foley, G. E., Friedman, O. M., and Drolet, B. P. Studies on the Mechanism of Action of Cytoxan. Evidence of Activation in Vivo and in Vitro. Cancer Res., 21: 57–63, 1961.
12. Friedman, O. M., and Boger, E. Colorimetric Estimation of Nitrogen Mustard in Aqueous Media. Anal. Chem., 33: 906–910, 1961.
13. 14C-Cyclophosphamide and Its Radioactive Metabolites in Rats Pretreated with Prednisolone. Biochem. Pharmacol., 21: 272–276, 1972.
14. Hayakawa, T., Kanai, N., Yamada, R., Kuroda, R., Higashi, H., Mogumi, H., and Jinnai, D. Effect of Steroid Hormone on Activation of Endoxan (Cyclophosphamide). Biochem. Pharmacol., 18: 129–135, 1969.
15. Hill, D. L., Laster, W. R., Jr., and Struck, R. F. Enzymatic Metabolism of Cyclophosphamide and Nicotine and Production of a Toxic Cyclophosphamide Metabolite. Cancer Res., 32: 658–665, 1972.
16. Hohorst, H. J., Ziemann, A., and Brock, N. 4-Ketocyclophosphamide, a Metabolite of Cyclophosphamide. Artzneimittel-Forsch., 21: 1254–1257, 1971.
17. Johns, D. G. Human Liver Aldehyde Oxidase: Differential Inhibition of Oxidation of Charged and Uncharged Substrates. J. Clin. Invest., 46: 1492–1505, 1967.
18. Livingston, R. B., and Carter, S. K. Single Agents in Cancer Chemotherapy. New York: Plenum Publishing Corp., 1970.
19. Mainland, D., Sutcliffe, M. I., Decker, J. L., Healey, L. A., Mikkelsen, W. M., Wallace, S. L., and Zvaifler, N. J. A Controlled Trial of Cyclophosphamide in Rheumatoid Arthritis. New. Engl. J. Med., 283: 883–889, 1970.
20. Mellett, J. B., Dareer El, S. M., Luce, J. K., and Frei, E., III. Activation of Cyclophosphamide Metabolism in Various Species. Pharmacologist, 11: 273, 1969.
21. Novack, S. N., and Pearson, C. M. Cyclophosphamide Therapy in Wegener's Granulomatosis. New Engl. J. Med., 284: 938–942, 1971.
22. Peterson, J. I. A Carbon Dioxide Collection Accessory for the Rapid Combustion Apparatus for Preparation of Biological Samples for Liquid Scintillation Analysis. Anal. Biochem., 31: 204–210, 1969.
23. Peterson, J. I., Wagner, F., Siegel, S., and Nixon, W. A System for Convenient Combustion Preparation of Tritiated Biological Samples for Scintillation Analysis. Anal. Biochem., 31: 189–203, 1969.
24. Sladek, N. E. Therapeutic Efficacy of Cyclophosphamide as a Function of Its Metabolism. Cancer Res., 32: 535–542, 1972.
25. Steinberg, A. D., Kaltreider, B., Staples, P. J., Goetzl, E. J., Talal, N., and Decker, J. L. Cyclophosphamide in Lupus Nephritis: A Controlled Trial. Ann. Internal Med., 75: 165–171, 1971.
26. Struck, R. F., and Hill, D. L. Investigation of the Synthesis of Aldophosphamide (AP), a Toxic Metabolite of Cyclophosphamide (CTX). Proc. Am. Assoc. Cancer Res., 13: 50, 1972.
27. Struck, R. F., Kirk, M. C., Mellett, L. B., Dareer El, S., and Hill, D. L. Urinary Metabolites of the Antitumor Agent Cyclophosphamide. Mol. Pharmacol., 7: 519–529, 1971.
28. Tanneberger, S. T., and Negelein, E. Ueber die zeitlich Ablauf der Aktivierung von Cyclophosphamid in Menschen und die Testung der zytostatisch activ Form an Ehrlich Maeuseazites-Tumorzellen. Experientia, 22: 549–550, 1966.
29. Tardiff, R. G., and Dubois, K. P. Inhibition of Hepatic Microsomal Enzymes by Alkylating Agents. Arch. Intern. Pharmacol., 177: 445–456, 1969.
30. Vesell, E. S., Passanti, G.T., and Greene F. E. Impairment of Drug Metabolism in Man by Allopurinol and Nortryptyline. New Engl. J. Med., 283: 1484–1488, 1970.